Clinical Trials Browser

Phase 3 × durvalumab × Genitourinary × Clear all

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT05943106 2026-03-11

PATAPSCO

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT05043090 2025-05-08

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03288532 2020-09-07

RAMPART

Phase 3 Recruiting

Carcinoma, Renal Cell